TABLE 8.

Evaluation of duration of protection of 1% 2V formulation of SPL7013 against genital herpes in mice

TreatmentConcn (mg/ml)Time (min) treated prior to challengeFraction (%) of animals protected against:
DiseaseInfection
SPL7013 formulation 2V1058/15 (53)a8/15 (53)a
SPL7013 formulation 2V10309/15 (60)a8/15 (53)a
SPL7013 formulation 2V10606/15 (40)b6/15 (40)b
PBS50/15 (0)0/15 (0)
SPL7013 formulation 2V1058/12 (67)a8/12 (67)a
SPL7013 formulation 2V10308/12 (67)a8/12 (67)a
PBS50/12 (0)0/12 (0)
  • a P < 0.01 versus PBS.

  • b P < 0.05 versus PBS.